alcohol-associated liver disease, hepatocellular carcinoma, cirrhosis, survival
Metabolic dysfunction-associated steatohepatitis, Network meta-analysis, Randomized Controlled Trial, metabolic and insulin-sensitizing agents, FGF21, GLP-1
MASLD, pemafibrate, fenofibrate
anti-angiogenic treatment, sprouting vessel, microRNA, miR139-3p, miR214-3p, hepatocellular carcinoma